Susan Sencer

ORCID: 0000-0001-6360-2728
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Childhood Cancer Survivors' Quality of Life
  • Complementary and Alternative Medicine Studies
  • Immunotherapy and Immune Responses
  • Sinusitis and nasal conditions
  • Herbal Medicine Research Studies
  • Testicular diseases and treatments
  • Infectious Diseases and Mycology
  • Pediatric Pain Management Techniques
  • Acute Lymphoblastic Leukemia research
  • RNA Interference and Gene Delivery
  • Pharmaceutical studies and practices
  • Neonatal Health and Biochemistry
  • Ethics and Legal Issues in Pediatric Healthcare
  • Antifungal resistance and susceptibility
  • Neuroblastoma Research and Treatments
  • Vascular Tumors and Angiosarcomas
  • Head and Neck Surgical Oncology
  • Palliative Care and End-of-Life Issues
  • Ovarian cancer diagnosis and treatment
  • Polyomavirus and related diseases
  • Sarcoma Diagnosis and Treatment
  • Phytochemistry Medicinal Plant Applications
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Congenital Anomalies and Fetal Surgery
  • Neurological and metabolic disorders

Children’s Minnesota - St. Paul Hospital
1997-2022

Children's Minnesota
2007-2019

Minnesota West Community & Technical College
2017

Helen DeVos Children's Hospital
2016

Istanbul University
2008

University of Minnesota
1987-2006

Palmetto Hematology Oncology
2006

University of Minnesota Children's Hospital
2004-2006

Abbott Northwestern Hospital
2003

Dana-Farber Cancer Institute
2003

Nearly 2000 children die due to a malignancy in the United States annually. Emerging data suggest that home is desired location of care for with cancer at end life. However, one obstacle enrollment pediatric palliative (PPC) program may be fear distressing symptoms life cannot adequately managed outside hospital.To compare symptom distress and quality-of-life experience who received concurrent end-of-life from PPC (PPC/Oncology) those died without exposure (Oncology).We conducted...

10.1089/jpm.2014.0285 article EN Journal of Palliative Medicine 2014-11-17

Abstract High risk neuroblastoma (HRNB) accounts for 15% of all pediatric cancer deaths. Despite aggressive therapy approximately half patients will relapse, typically with only transient responses to second-line therapy. This study evaluated the ornithine decarboxylase inhibitor difluoromethylornithine (DFMO) as maintenance prevent relapse following completion standard (Stratum 1) or after salvage relapsed/refractory disease 2). Phase II single agent, arm multicenter enrolled from June 2012...

10.1038/s41598-018-32659-w article EN cc-by Scientific Reports 2018-09-21

Hemorrhagic cystitis (HC) is a major cause of morbidity after BMT; we have analyzed its incidence, risk factors, and complications in 977 patients undergoing BMT between 1974 1988. Despite vigorous hydration frequent voiding all receiving cyclophosphamide, 135/977 (15% by Kaplan-Meier projection) developed HC (micro- or gross hematuria, dysuria, bladder pain) −11 +100 days (median +22) BMT. Of these, 60 had severe HC, including urinary obstruction (4/60), renal failure (13/60), need for...

10.1097/00007890-199310000-00020 article EN Transplantation 1993-10-01

The objective of this survey is to determine the frequency, reasons, and factors influencing use complementary alternative medicine (CAM) in general specialty pediatrics within same geographic area. Of 281 surveys completed, CAM was higher children with epilepsy (61.9%), cancer (59%), asthma (50.7%), sickle cell disease (47.4%) than (36%). Children most often used prayer (60.5%), massage (27.9%), vitamins (27.2%), chiropractic care (25.9%), dietary supplements (21.8%). Parents who for...

10.1177/1043454208323914 article EN Journal of Pediatric Oncology Nursing 2008-10-20

This pilot study aimed to determine the feasibility of providing massage children with cancer reduce symptoms in and anxiety parents. Twenty-three children/parent dyads were enrolled; 17 completed all data points. Children cancer, ages 1 18 years, received at least 2 identical cycles chemotherapy, one parent, participated 2-period crossover design which 4 weekly sessions alternated quiet-time control sessions. Changes relaxation (heart respiratory rates, blood pressure, salivary cortisol...

10.1177/1043454208323295 article EN Journal of Pediatric Oncology Nursing 2008-10-20

Nonsurgical treatment of lymphangiomas has shown limited efficacy and often carries unacceptable toxicities, demonstrating the need for a more effective, less toxic therapy.We describe two patients with lymphangiomatosis treated 12 to 40 months recombinant interferon-alpha.Both demonstrated stabilization or marked improvement disease, based on clinical radiologic findings, minimal toxicity.The favorable responses interferon-alpha therapy in these cases suggest that this is an effective...

10.1097/00043426-199705000-00010 article EN Journal of Pediatric Hematology/Oncology 1997-05-01

Chemotherapy may cause neuromuscular impairments that can have life-long effects. The Stoplight Program (SLP) was developed as a proactive physical therapy (PT) intervention directed at in children with acute lymphoblastic leukemia (ALL). In this program evaluation, we assessed the feasibility of SLP delivered part standard care and identified body function activity patterns patients who received intervention. Children ages 1 to 22 years, diagnosed ALL, an assessment by therapist usual care....

10.1177/1043454217698093 article EN Journal of Pediatric Oncology Nursing 2017-04-29

Due to rapid clearance of interleukin-2 (IL-2), it has had limited effective use as an in vivo immunostimulant. Current experimental and clinical protocols generally must utilize large doses, multiple injections, or continuous infusions IL-2 order achieve significant immunostimulation, often at the expense systemic toxicity. Therefore, pharmacodynamics liposomes were investigated. liposome incorporation efficiency was 80.4% (SD 5.5); vesicle diameter 1.65 microns 0.09) determined by...

10.1097/00002371-199207000-00003 article EN Journal of Immunotherapy 1992-07-01

Over 50% of patients with rhabdomyosarcoma (RMS) have intermediate risk disease, a 3-year failure-free survival (FFS) 50%-70% depending on histology. Doxorubicin is active against RMS, but its role in improving outcome remains controversial. Ifosfamide as cyclophosphamide the Fourth Intergroup RMS Study (IRS-IV) showing equivalent outcomes for treated ifosfamide first 28 weeks compared to cyclophosphamide. Treatment alternating cycles non-cross-resistant chemotherapy has been used number...

10.1002/pbc.21093 article EN Pediatric Blood & Cancer 2006-11-07

Little information is available on the use of complementary and alternative medicine (CAM) in long-term survivors childhood adolescent cancer.The Childhood Cancer Survivor Study (CCSS) a resource evaluating effects cancer associated therapies 5-year diagnosed between 1970 1986 before age 21 years. A survey CAM during previous year was distributed 2000-2001 completed by 9,984 2,474 sibling controls.CAM reporting similar cases (39.4%) siblings (41.1%). Compared to female siblings, were more...

10.1002/pbc.21177 article EN Pediatric Blood & Cancer 2007-03-15

To evaluate the management and outcomes of children with invasive fungal sinonasal disease treated radical surgery.Retrospective case series.From 1994 to 2007, 11 pediatric patients were identified surgically by same otolaryngologist. Collected data included demographics, oncologic diagnoses, absolute neutrophil counts, symptoms, computed tomography scan findings, biopsy culture results, surgical procedures, concurrent medical therapies, complications, survival.The studied patient population...

10.1002/lary.24369 article EN The Laryngoscope 2013-10-08

The purpose of this pharmacoeconomic analysis was to compare pegaspargase. a newer chemotherapeutic agent used for treating acute lymphoblastic leukemia, with native Escherichia coli L-asparaginase in induction, delayed intensification 1 and 2.A subset patients newly diagnosed, standard-risk, leukemia enrolled the Children's Cancer Group (CCG) study CCG-1962 at seven participating institutions gave consent our study. Societal (transportation, lodging, missed workdays, food, babysitter) payer...

10.1097/00043426-200203000-00004 article EN Journal of Pediatric Hematology/Oncology 2002-03-01

Abstract Incorporation of interleukin‐2 (IL‐2) into multilamellar vesicles, IL‐2 liposomes, significantly modifies the biodistribution and prolongs clearance cytokine. The rat was used to evaluate characterize subacute toxicity short‐term pathologic effects intravenous (i.v.) liposomes. Once daily i.v. liposomes in doses 0.3 × 10 6 u/kg, 1.5 4.0 20 u/kg were given rats for 15 days; control received empty or buffered saline. Hematologic parameters, serum chemistry, gross histopathologic...

10.1002/ddr.430270103 article EN Drug Development Research 1992-01-01

Cancer and its treatment can lead to functional limitations affecting ongoing development in children adolescents. We developed a pediatric cancer rehabilitation program that integrates evidence-based rehabilitative care into treatment. The utilizes the CREATE (collaboration, rehabilitation/research, education, assessment, treatment, evaluation) Childhood Rehabilitation model. aim describe structural process components of our provide an access utilization analysis.To evaluate program, we...

10.1002/pbc.29912 article EN Pediatric Blood & Cancer 2022-08-20
Coming Soon ...